IL293367A - Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia - Google Patents

Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia

Info

Publication number
IL293367A
IL293367A IL293367A IL29336722A IL293367A IL 293367 A IL293367 A IL 293367A IL 293367 A IL293367 A IL 293367A IL 29336722 A IL29336722 A IL 29336722A IL 293367 A IL293367 A IL 293367A
Authority
IL
Israel
Prior art keywords
seq
chain variable
antibody
variable region
drug delivery
Prior art date
Application number
IL293367A
Other languages
English (en)
Hebrew (he)
Inventor
Debra A Freedholm
Daniel M Bloomfield
Royston J Glasspool
Jonathan E Freeman
Original Assignee
Anthos Therapeutics Inc
Debra A Freedholm
Daniel M Bloomfield
Royston J Glasspool
Jonathan E Freeman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc, Debra A Freedholm, Daniel M Bloomfield, Royston J Glasspool, Jonathan E Freeman filed Critical Anthos Therapeutics Inc
Publication of IL293367A publication Critical patent/IL293367A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IL293367A 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia IL293367A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951887P 2019-12-20 2019-12-20
PCT/US2020/066151 WO2021127525A1 (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies

Publications (1)

Publication Number Publication Date
IL293367A true IL293367A (en) 2022-07-01

Family

ID=76478578

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293367A IL293367A (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia

Country Status (9)

Country Link
US (1) US20230071973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076511A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023507795A (cg-RX-API-DMAC7.html)
KR (1) KR20220119090A (cg-RX-API-DMAC7.html)
CN (1) CN115003325A (cg-RX-API-DMAC7.html)
BR (1) BR112022012064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161118A1 (cg-RX-API-DMAC7.html)
IL (1) IL293367A (cg-RX-API-DMAC7.html)
WO (1) WO2021127525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies
EP4461749A4 (en) * 2022-01-05 2025-03-26 Shanghai Mabgen Biotech Ltd. Pharmaceutical composition containing anti-FXI/FXIA antibodies and use thereof
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子xi/因子xia抗體之組合療法
DE102022116219A1 (de) * 2022-06-29 2024-01-04 St. Jude Medical, Cardiology Division, Inc. Kandidatenscreening für eine Zieltherapie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
WO2008039761A2 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
JOP20160131B1 (ar) * 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
KR102616666B1 (ko) * 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PT3570882T (pt) * 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies

Also Published As

Publication number Publication date
BR112022012064A2 (pt) 2022-08-30
JP2023507795A (ja) 2023-02-27
KR20220119090A (ko) 2022-08-26
EP4076511A4 (en) 2024-02-14
US20230071973A1 (en) 2023-03-09
WO2021127525A1 (en) 2021-06-24
EP4076511A1 (en) 2022-10-26
CN115003325A (zh) 2022-09-02
CA3161118A1 (en) 2021-06-24
JP2026048712A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
CN111315411B (zh) 高浓度抗c5抗体制剂
US20230071973A1 (en) Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
KR20180094028A (ko) 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
US12286472B2 (en) Biopharmaceutical compositions and methods for pediatric patients
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
US12351624B2 (en) Compositions and methods for treating synucleinopathies
TW202434633A (zh) 治療甲狀腺眼疾之方法
KR20250107839A (ko) 심혈관계 질환의 치료 방법
JP2023532287A (ja) 疼痛の治療における使用のためのTGF-α及びエピレグリンに結合する抗体
EP4543434A2 (en) Combination therapies with an anti-factor xi/factor xia antibody
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
JP7798763B2 (ja) C5関連疾患の治療または予防のための投与レジメン
BR112021010414A2 (pt) Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease
CN118302196A (zh) 因子XI/XIa抗体的给药方案
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека